ARCHIVES

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

President, First Lady Visit Clinical Center, Hail ‘Compassion’

January 5, 1990

ImClone Founding CEO Samuel Waksal Charged With Securities Fraud, Conspiracy, Perjury

June 14, 2002

In Brief: New NIH Grant Program Offers Up To $1 Million a Year For Centers At Minority Institutions

January 25, 1985

Older Patients Tolerate Chemo, Decline Due To Severe Toxicity

February 28, 2003

Atrix, Sanofi In Marketing Deal For Leuprogel Products.

January 26, 2001

Brachytherapy Better Than Surgery For Prostate Cancer

October 29, 2004